Current Neuro-Oncology

Volume 26 Number 1
15 January 2024

Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 1, 15 January

Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Thon N, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC.
Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group.
Neuro Oncol. 2024 Jan 2:noad237. doi: 10.1093/neuonc/noad237. PMID: 38164632. Letter, Observational study˰ ˍ

*Zhao L, Qiu Z, Yang Z, Xu L, Pearce TM, Wu Q, Yang K, Li F, Saulnier O, Fei F, Yu H, Gimple RC, Varadharajan V, Liu J, Hendrikse LD, Fong V, Wang W, Zhang J, Lv D, Lee D, Lehrich BM, Jin C, Ouyang L, Dixit D, Wu H, Wang X, Sloan AE, Wang X, Huan T, Mark Brown J, Goldman SA, Taylor MD, Zhou S, Rich JN.
Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism.
Nat Cancer. 2024 Jan 3;5(1):147-166. doi: 10.1038/s43018-023-00658-0. PMID: 38172338. Laboratory investigation˰ ˍ
Related article:
Brewer G.
Cholesterol-fuelled glioblastoma.
Nat Rev Cancer. 2024 Jan 31. doi: 10.1038/s41568-024-00672-z. PMID: 38297143. Comment˰ ˍ

*Silvani A, Franceschi E.
A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Tumori. 2024 Jan 2:3008916231217583. doi: 10.1177/03008916231217583. PMID: 38166539. Editorial. ˍ
Related article:
Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304194. PMID: 37272516. Interventional study. ˍ

Zhao S, Zhang M, Zhang Q, Wu J, Dai H.
Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
BMC Cancer. 2024 Jan 2;24(1):6. doi: 10.1186/s12885-023-11776-4. PMID: 38166698. Interventional study. ˍ

Koyuncuer A.
Intraoperative Touch Imprint Cytology of Brain Neoplasms: A Useful High-Diagnostic Tool in 93 Consecutive Cases; Differential Diagnoses, Pitfalls, and Traps.
Anal Cell Pathol (Amst). 2024 Jan 4;2024:2346092. doi: 10.1155/2024/2346092. PMID: 38440121. Observational study. ˍ


Shi ZF, Li KK, Liu AP, Chung NY, Chow C, Chen H, Kan NA, Zhu XL, Chan DT, Mao Y, Ng HK.
Rare Pediatric Cerebellar High-Grade Gliomas Mimic Medulloblastomas Histologically and Transcriptomically and Show p53 Mutations.
Cancers (Basel). 2024 Jan 4;16(1):232. doi: 10.3390/cancers16010232. PMID: 38201659. Case report. ˍ

Stepien N, Mayr L, Schmook MT, Raimann A, Dorfer C, Peyrl A, Azizi AA, Schramm K, Haberler C, Gojo J.
Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Pediatr Blood Cancer. 2024 Jan 4:e30836. doi: 10.1002/pbc.30836. PMID: 38177074. Case report. ˍ

*Wang S, Yin F, Guo Z, Li R, Sun W, Wang Y, Geng Y, Sun C, Sun D.
Association between gut microbiota and glioblastoma: a Mendelian randomization study.
Front Genet. 2024 Jan 4;14:1308263. doi: 10.3389/fgene.2023.1308263. PMID: 38239850. Observational study. ˍ

Zhang JF, Okai B, Iovoli A, Goulenko V, Attwood K, Lim J, Hess RM, Abad AP, Prasad D, Fenstermaker RA.
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma.
J Neurooncol. 2024 Jan 4. doi: 10.1007/s11060-023-04524-y. PMID: 38175460. Observational study. ˍ

Sun Y, Liu P, Wang Z, Zhang H, Xu Y, Hu S, Yan Y.
Efficacy and indications of gamma knife radiosurgery for recurrent low-and high-grade glioma.
BMC Cancer. 2024 Jan 5;24(1):37. doi: 10.1186/s12885-023-11772-8. PMID: 38183008. Observational study. ˍ

André N, Deley MCL, Léguillette C, Probst A, Willems L, Travers R, Aerts I, Faure-Conter C, Revond-Riviere G, Min V, Geoerger B, Chastagner P, Entz-Werlé N, Leblond P.
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors.
Eur J Cancer. 2024 Jan 6;198:113525. doi: 10.1016/j.ejca.2024.113525. PMID: 38199147. Interventional study. ˍ

Bobholz SA, Hoefs A, Hamburger J, Lowman AK, Winiarz A, Duenweg SR, Kyereme F, Connelly J, Coss D, Krucoff M, Banerjee A, LaViolette PS.
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
Res Sq [Preprint]. 2024 Jan doi: 10.21203/ PMID: 38260400. Observational study. ˍ

Naeem A, Aziz N, Nasir M, Rangwala HS, Fatima H, Mubarak F.
Accuracy of MRI in Detecting 1p/19q Co-deletion Status of Gliomas: A Single-Center Retrospective Study.
Cureus. 2024 Jan 8;16(1):e51863. doi: 10.7759/cureus.51863. PMID: 38327950. Observational study. ˍ

Pilbeam KL, Pradhan K, Croop J, Minard CG, Liu X, Voss SD, Isikwei E, Berg SL, Reid JM, Fox E, Weigel BJ.
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pediatr Blood Cancer. 2024 Jan 8:e30817. doi: 10.1002/pbc.30817. PMID: 38189770. Interventional study˰ ˍ

Roux A, Elia A, Aboubakr O, Moiraghi A, Simboli GA, Tauziede-Espariat A, Dezamis E, Parraga E, Benevello C, Fathallah H, Chretien F, Oppenheim C, Zanello M, Pallud J.
Efficacy and Safety of Carmustine Wafer Implantation After Ventricular Opening in Glioblastomas, Isocitrate Dehydrogenase-Wildtype, in Adults.
Neurosurgery. 2024 Jan 8. doi: 10.1227/neu.0000000000002817. PMID: 38189433. Observational study˰ ˍ

Derby S, Jackson MR, Williams K, Stobo J, Kelly C, Sweeting L, Shad S, Herbert C, Short SC, Williamson A, James A, Nowicki S, Bulbeck H, Chalmers AJ.
Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial.
Int J Radiat Oncol Biol Phys. 2024 Jan 9:S0360-3016(24)00015-4. doi: 10.1016/j.ijrobp.2024.01.011. PMID: 38211641. Interventional study. ˍ

Jimenez AE, Chakravarti S, Liu J, Kazemi F, Jackson C, Gallia G, Bettegowda C, Weingart J, Brem H, Mukherjee D.
The Hospital Frailty Risk Score independently predicts postoperative outcomes in glioblastoma patients.
World Neurosurg. 2024 Jan 9:S1878-8750(24)00033-0. doi: 10.1016/j.wneu.2024.01.021. PMID: 38211815. Observational study˰ ˍ

Li Z, Song Y, Farrukh Hameed NU, Yuan S, Wu S, Gong X, Zhuang D, Lu J, Zhu F, Qiu T, Zhang J, Aibaidula A, Geng X, Yang Z, Tang W, Chen H, Zhou L, Mao Y, Wu J.
Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial.
Eur J Cancer. 2024 Jan 9;199:113528. doi: 10.1016/j.ejca.2024.113528. PMID: 38218157. Interventional study˰ ˍ

Hatiboglu MA, Akdur K, Sakarcan A, Seyithanoglu MH, Turk HM, Sinclair G, Oztanir MN.
Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy.
Neurochirurgie. 2024 Jan 10;70(2):101532. doi: 10.1016/j.neuchi.2024.101532. PMID: 38215936. Observational study˰ ˍ

Freund BE, Jaeckle K, Quinones-Hinojosa A, Feyissa AM.
Case Report: "Aggressive" perioperative antiseizure medication prophylaxis in patients with glioma-related epilepsy at high risk of early postoperative seizures following awake craniotomy.
Front Surg. 2024 Jan 11;10:1282013. doi: 10.3389/fsurg.2023.1282013. PMID: 38274353. Case report. ˍ

Gatto L, Di Nunno V, Tosoni A, Bartolini S, Ranieri L, Franceschi E.
Vorasidenib in IDH1/2-mutant low-grade glioma: the grey zone of patient's selection.
Front Oncol. 2024 Jan 11;13:1339266. doi: 10.3389/fonc.2023.1339266. PMID: 38273856. Comment. ˍ
Related article:
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304194. PMID: 37272516. Interventional study. ˍ

Neef V, König S, Becker H, Dubinski D, Flinspach A, Raimann FJ, Weber K, Ronellenfitsch MW, Konczalla J, Hattingen E, Czabanka M, Senft C, Zacharowski K, Baumgarten P.
Red blood cell transfusion in patients undergoing elective primary glioblastoma resection.
Blood Transfus. 2024 Jan 11. doi: 10.2450/BloodTransfus.613. PMID: 38315541. Observational study. ˍ

Romano A, Sollazzo F, Rivetti S, Morra L, Servidei T, Lucchetti D, Attinà G, Maurizi P, Mastrangelo S, Zovatto IC, Monti R, Bianco M, Palmieri V, Ruggiero A.
Evaluation of Metabolic and Cardiovascular Risk Measured by Laboratory Biomarkers and Cardiopulmonary Exercise Test in Children and Adolescents Recovered from Brain Tumors: The CARMEP Study.
Cancers (Basel). 2024 Jan 11;16(2):324. doi: 10.3390/cancers16020324. PMID: 38254811. Observational study. ˍ

Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA, Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W, Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K, Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
Nat Cancer. 2024 Jan 12. doi: 10.1038/s43018-023-00709-6. PMID: 38216766. Interventional study˰ ˍ

Galanis E, Dooley KE, Keith Anderson S, Kurokawa CB, Carrero XW, Uhm JH, Federspiel MJ, Leontovich AA, Aderca I, Viker KB, Hammack JE, Marks RS, Robinson SI, Johnson DR, Kaufmann TJ, Buckner JC, Lachance DH, Burns TC, Giannini C, Raghunathan A, Iankov ID, Parney IF.
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
Nat Commun. 2024 Jan 12;15(1):493. doi: 10.1038/s41467-023-43076-7. PMID: 38216554. Interventional study. ˍ

van der Meulen M, Ramos RC, Voisin MR, Patil V, Wei Q, Singh O, Climans SA, Kalidindi N, Or R, Aldape K, Diamandis P, Munoz DG, Zadeh G, Mason WP.
Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
Neurooncol Adv. 2024 Jan 12;6(1):vdae001. doi: 10.1093/noajnl/vdae001. PMID: 38312227. Observational study. ˍ

Flies CM, Friedrich M, Lohmann P, van Garderen KA, Smits M, Tonn JC, Weller M, Galldiks N, Snijders TJ.
Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.
Neuro Oncol. 2024 Jan 14:noad247. doi: 10.1093/neuonc/noad247. PMID: 38219019. Observational study. ˍ

Bhaskaran D, Savage J, Patel A, Collinson F, Mant R, Boele F, Brazil L, Meade S, Buckle P, Lax S, Billingham L, Short SC.
A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
BMC Cancer. 2024 Jan 15;24(1):83. doi: 10.1186/s12885-023-11792-4. PMID: 38225549. Interventional study protocol. ˍ

Chen ATC, Serante AR, Ayres AS, Tonaki JO, Moreno RA, Shih H, Gattás GS, Lopez OVM, Reis Dos Santos de Jesus G, de Carvalho IT, Marotta RC, Marta GN, Feher O, Neto HS, Ribeiro ISN, da Conceição Vasconcelos KGM, Figueiredo EG, Weltman E.
Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiotherapy of 25 Gy in 5 fractions compared to 35 Gy in 5 fractions in the Reirradiation of Recurrent Glioblastoma.
Int J Radiat Oncol Biol Phys. 2024 Jan 15:S0360-3016(24)00026-9. doi: 10.1016/j.ijrobp.2024.01.013. PMID: 38232937. Interventional study˰ ˍ

*Georgescu MM.
Translation into Clinical Practice of the G1-G7 Molecular Subgroup Classification of Glioblastoma: Comprehensive Demographic and Molecular Pathway Profiling.
Cancers (Basel). 2024 Jan 15;16(2):361. doi: 10.3390/cancers16020361. PMID: 38254850. Laboratory investigation, Observational study. ˍ

Kikuchi K, Togao O, Yamashita K, Momosaka D, Kikuchi Y, Kuga D, Yuhei S, Fujioka Y, Narutomi F, Obara M, Yoshimoto K, Ishigami K.
Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Neuroradiology. 2024 Jan 15. doi: 10.1007/s00234-024-03288-0. PMID: 38224343. Observational study. ˍ

Kushihara Y, Tanaka S, Kobayashi Y, Nagaoka K, Kikuchi M, Nejo T, Yamazawa E, Nambu S, Kugasawa K, Takami H, Takayanagi S, Saito N, Kakimi K.
Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression.
Front Immunol. 2024 Jan 15;15:1328375. doi: 10.3389/fimmu.2024.1328375. PMID: 38288307. Laboratory investigation, Observational study. ˍ

Losurdo A, Dipasquale A, Giordano L, Persico P, Lorenzi E, Di Muzio A, Barigazzi C, Korolewicz J, Mehan A, Mohammed O, Scheiner B, Pinato DJ, Santoro A, Simonelli M.
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.
Front Immunol. 2024 Jan 15;15:1323151. doi: 10.3389/fimmu.2024.1323151. PMID: 38298193. Observational study. ˍ

Mastall M, Roth P, Bink A, Fischer Maranta A, Läubli H, Hottinger AF, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobagyi T, Held L, Weller M, Wirsching HG.
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
BMC Cancer. 2024 Jan 15;24(1):82. doi: 10.1186/s12885-023-11797-z. PMID: 38225589. Interventional study protocol. ˍ